Business Context and Reporting Period
This Form 8-K is a current report filed by Aeglea BioTherapeutics, Inc. (not Spyre Therapeutics, Inc.) on June 7, 2019. The filing documents the results of the Company's 2019 Annual Meeting of Stockholders held on the same date. The Company is incorporated in Delaware and its common stock trades on the Nasdaq Global Market under the symbol "AGLE".
Key Financial Metrics
This filing is a corporate governance report regarding shareholder votes and does not contain financial performance data. There is no information provided regarding revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
The filing reports the following material corporate actions approved by shareholders:
- Director Elections: Three Class III directors were elected to three-year terms expiring at the 2022 Annual Meeting: Armen Shanafelt, Ph.D., V. Bryan Lawlis, Ph.D., and Anthony G. Quinn, M.B Ch.B, Ph.D.
- Accounting Firm Ratification: Shareholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2019.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, or specific risk factors. It strictly details the voting results of the annual meeting.
Investor Verification Checklist
- Verify the correct registrant name is Aeglea BioTherapeutics, Inc. (AGLE), as the input metadata incorrectly referenced Spyre Therapeutics.
- Confirm the election results for the three new directors and their term expiration dates (2022).
- Note the significant number of broker non-votes (5,226,615) recorded for the director elections.
- Review the Company's most recent 10-K or 10-Q filings for actual financial metrics, as this 8-K contains none.